Globus Medical (GMED) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Globus Medical stock (GMED) is currently trading at $87.35. Globus Medical PE ratio is 22.00. Globus Medical PS ratio (Price-to-Sales) is 3.97. Analyst consensus price target for GMED is $110.08. WallStSmart rates GMED as Moderate Buy.
- GMED PE ratio analysis and historical PE chart
- GMED PS ratio (Price-to-Sales) history and trend
- GMED intrinsic value — DCF, Graham Number, EPV models
- GMED stock price prediction 2025 2026 2027 2028 2029 2030
- GMED fair value vs current price
- GMED insider transactions and insider buying
- Is GMED undervalued or overvalued?
- Globus Medical financial analysis — revenue, earnings, cash flow
- GMED Piotroski F-Score and Altman Z-Score
- GMED analyst price target and Smart Rating
Globus Medical
📊 No data available
Try selecting a different time range
GMED Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Globus Medical (GMED)
GMED trades at a significant discount to its Graham intrinsic value of $183.46, offering a 52% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Globus Medical (GMED) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Globus Medical (GMED) Key Strengths (6)
Earnings per share surging 437.00% year-over-year
102.22% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $24 kept per $100 revenue
Strong revenue growth at 25.70% annually
Strong profitability: $18 kept per $100 revenue
Supporting Valuation Data
Globus Medical (GMED) Areas to Watch (4)
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Revenue is fairly priced at 3.97x sales
Fairly priced relative to book value
Globus Medical (GMED) Detailed Analysis Report
Overall Assessment
This company scores 74/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 5.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Market Cap. Profitability is solid with Operating Margin at 24.40%, Profit Margin at 18.30%. Growth metrics are encouraging with Revenue Growth at 25.70%, EPS Growth at 437.00%.
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (1.73), Price/Sales (3.97), Price/Book (2.55) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 12.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 25.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of EPS Growth and Institutional Own. makes a compelling case at current levels. The key risk is Return on Equity, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GMED Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GMED's Price-to-Sales ratio of 3.97x trades 36% below its historical average of 6.2x (12th percentile). The current valuation is 66% below its historical high of 11.74x set in Jul 2021, and 65% above its historical low of 2.41x in Jul 2025. Over the past 12 months, the PS ratio has expanded from ~3.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Globus Medical (GMED) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Globus Medical is a strong growth company balancing expansion with improving profitability. Revenue reached 2.9B with 26% growth year-over-year. Profit margins of 18.3% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 26% YoY, reaching 2.9B. This pace significantly outperforms most MEDICAL DEVICES peers.
Generating 192M in free cash flow and 249M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Globus Medical maintain 26%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Globus Medical.
Bottom Line
Globus Medical offers an attractive blend of growth (26% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(23 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:52:42 AM
About Globus Medical(GMED)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.